Skip to main
  1. Stocks
  2. Dyne Therapeutics
  3. Forecast
DYN

Dyne Therapeutics (DYN) Stock Forecast & Price Target

Dyne Therapeutics (DYN) Analyst Ratings

Based on 11 analyst ratings
Buy
Strong Buy 27%
Buy 45%
Hold 18%
Sell 9%
Strong Sell 0%

Bulls say

Dyne Therapeutics is attractive fundamentally because its FORCE platform is designed to solve one of the hardest problems in neuromuscular disease—delivering therapy to muscle and CNS—using TfR1-Fab-mediated delivery and indication-specific payloads. In DM1, DYNE-101 has shown pooled 12-month gains across vHOT, 5xSTS, QMT, and MDHI, plus movement across six CNS subscales, while safety remains encouraging with 143 patient-years and no related serious TEAEs. The thesis is further strengthened by DYNE-251’s ~10x dystrophin levels versus SOC in DMD, and by HARMONIA’s 150-patient, 48-week design that targets functional endpoints more aligned with real-world benefit.

Bears say

Dyne Therapeutics is viewed negatively because the DM1 program’s lead study, ACHIEVE-REC, carries materially lower-than-assumed statistical power after accounting for high placebo-arm variability, which cuts confidence in a clean readout and weakens the investment case. The company also chose to keep the trial small at N=71 despite Novartis’ larger N=159 failure, while the lack of individual-patient splicing data and weak linkage between splicing gains and vHOT benefit leave regulators and investors uncertain about true clinical translation. As a development-stage company with no revenue, continuing cash burn, and likely future debt or equity financing that could dilute holders, Dyne also faces meaningful financing and execution risk alongside safety, regulatory, and competition concerns.

Dyne Therapeutics (DYN) has been analyzed by 11 analysts, with a consensus rating of Buy. 27% of analysts recommend a Strong Buy, 45% recommend Buy, 18% suggest Holding, 9% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Dyne Therapeutics and is not a guaranteed prediction by Public.com or investment advice.

Dyne Therapeutics (DYN) Analyst Forecast & Price Prediction

Get the latest Dyne Therapeutics (DYN) stock forecast, including analyst ratings and price predictions, with real-time AI-powered fundamental data and custom analysis

Start investing in Dyne Therapeutics (DYN)

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Dyne Therapeutics (DYN) Forecast

Analysts have given Dyne Therapeutics (DYN) a Buy based on their latest research and market trends.

According to 11 analysts, Dyne Therapeutics (DYN) has a Buy consensus rating as of Nov 20, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $30, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $30, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Dyne Therapeutics (DYN)


Dyne Therapeutics (DYN) Analyst Forecast & Price Prediction

Get the latest Dyne Therapeutics (DYN) stock forecast, including analyst ratings and price predictions, with real-time AI-powered fundamental data and custom analysis

Start investing in Dyne Therapeutics (DYN)

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.
Uncover DYN stock data and trends